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ABSTRACT:
Epithelial-to-mesenchymal transition (EMT) plays an important role in prostate cancer 
(PCa) metastasis. The transcription/translation regulatory Y-box binding protein-1 (YB-1) is 
known to be associated with cancer metastasis. We observed that YB-1 expression increased 
with tumor grade and showed an inverse relationship with E-cadherin in a human PCa tissue 
array. Forced YB-1 expression induced a mesenchymal morphology that was associated with 
down regulation of epithelial markers. Silencing of YB-1 reversed mesenchymal features and 
decreased cell proliferation, migration and invasion in PCa cells. YB-1 is activated directly via Akt 
mediated phosphorylation at Ser102 within the cold shock domain (CSD). We next identified fisetin 
as an inhibitor of YB-1 activation. Computational docking and molecular dynamics suggested 
that fisetin binds on the residues from β1 - β4 strands of CSD, hindering Akt’s interaction 
with YB-1. Calculated free binding energy ranged from -11.9845 to -9.6273 kcal/mol. Plasmon 
Surface Resonance studies showed that fisetin binds to YB-1 with an affinity of approximately 
35 µM, with both slow association and dissociation. Fisetin also inhibited EGF induced YB-1 
phosphorylation and markers of EMT both in vitro and in vivo. Collectively our data suggest that 
YB-1 induces EMT in PCa and identify fisetin as an inhibitor of its activation.
INTRODUCTION
Prostate cancer (PCa) is the leading cause of cancer 
related deaths among American men. When detected 
early the five year survival rate is close to 100% however, 
detection at advanced metastatic stages severely declines 
the overall survival [1]. These statistics suggest that high 
mortality in PCa patients is due to metastasis. Metastasis 
is a multistep process by which cancer cells disseminate 
from their primary site to form secondary tumors at a 
distant site. Metastasis involves a series of steps including 
local invasion, intravasation, transport, extravasation, and 
colonization. 
During embryonic development cells travel long 
distances to reach their final destinations. To achieve 
this, epithelial cells rely on a very fine tuned and highly 
regulated program known as epithelial to mesenchymal 
transition (EMT) that converts them into a mesenchymal 
state. Cancer cells use this program to metastasize and 
colonize at distant sites [2]. Often the metastatic EMT 
resembles the molecular landscape of the developmental 
EMT such as loss of cell-cell junctions, apico-basal 
polarity and inheritance of migratory and invasive 
features. The EMT program is primarily orchestrated 
by one or several transcription factors (TF), mainly in 
response to variety of extracellular signals like EGF, FGF, 
IGF, TGF-β etc. [3]. The classical family of TF include 
Snail, Twist, Zeb, Slug etc.[4-6]. Recent research has 
added numerous new proteins than can direct the EMT 
program either directly or indirectly by inducing the 
classical TF. Among them Y-box–binding protein-1 (YB-
1) is a recently identified protein known to induce EMT in 
different cancers [7].
YB-1 is a broad-specificity RNA-binding protein, 
mainly involved in regulation of mRNA transcription, 
splicing, translation, and stability [8]. Recent literature 
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suggests its important role in a variety of cancers including 
prostate [9]. YB-1 plays various biologic roles in both the 
nucleus and the cytoplasm; however, as a transcription 
factor within the nucleus, YB-1 regulates the expression 
of several genes, including proliferating cell nuclear 
antigen, epidermal growth factor receptor (EGFR), 
DNA topoisomerase II, CD44, phosphotidylinositol-4,5-
biphosphat 3-kinase, (PIK3CA,and MET) [10-14]. In PCa 
YB-1 is associated with cell growth, anti-apoptosis, and 
multi drug resistance [15-16]. YB-1 directly regulates 
androgen receptor transcription and was found to be 
upregulated during androgen ablated tumor progression 
in a mouse xenograft model, suggesting that YB-1 plays 
a role in the progression of both androgen-dependent 
and castrate resistant PCa [17]. YB-1 is well linked with 
Twist1 that regulates YB-1 transcription upstream in PCa 
[18]. Similarly YB-1 induces the expression of clusterin, 
an important EMT mediator [19], clearly suggesting some 
involvement of YB-1 in EMT during PCa progression. 
Based on existing literature it is clearly evident that YB-1 
is associated with a variety of cancers including prostate 
and has been specifically projected as an interesting drug 
target.
Bioactive food components including plant 
polyphenols are known to have potent anticarcinogenic 
activities [20]. An important advantage with plant based 
polyphenols, especially those from dietary sources, is that 
they are perceived as non-toxic and have wide human 
acceptance [21]. Fisetin (3,7,3’,4’-tetrahydroxyflavone) 
belongs to such a  flavonol subgroup of flavonoids along 
with quercetin, myricetin and kaempferol. It is present 
in many fruits and vegetables most notably strawberries, 
apples, persimmons, kiwis, cucumbers and onions. We 
have previously shown that, fisetin acts as a dual inhibitor 
of the PI3K/Akt and the mTOR pathways [22]. Also fisetin 
induces cell cycle arrest, inhibits androgen signalling and 
tumor growth in prostate cancer models [23-24]. 
In the current study we demonstrate that YB-1 
expression leads to a change in cellular morphology 
towards a mesenchymal phenotype and induces migration 
and invasion of cells. We also identify a small molecule 
fisetin that interacts within the cold shock domain (CSD) 
domain of YB-1 and inhibits its phosphorylation at Ser102 
both in vitro and in in vivo.    
RESULTS
YB1 is overexpressed and inversely associated 
with E-cadherin in PCa
To determine whether YB-1 levels and localization 
correlate with Gleason grade in PCa, YB-1 staining 
was evaluated in a tissue array of benign, low (Gleason 
grade 2), intermediate (Gleason grade 3), and high 
grade (Gleason grade 4 or 5) PCa. In the benign prostate 
acini, YB-1 is expressed at a low level and is primarily 
localized in the cytoplasm of epithelial cells. Following 
transformation from benign to malignant, YB-1 expression 
levels are elevated and also demonstrate an increased 
expression in both peri-nuclear and nuclear spaces along 
with cytoplasmic localization (Supplementary Fig. 
1). These results clearly suggest that YB-1 increases 
throughout malignant progression with increase in Gleason 
grade. Next, we compared the expression of E-cadherin in 
the same tissue samples by using dual labeling. Results 
showed significant inverse relation between E-cadherin 
and YB-1 in high grade prostate tissue samples when 
compared with low grade prostate tissue samples (Fig. 1A 
& B). Overall these results confirm an inverse relationship 
in E-cadherin/YB-1 ratio in high grade PCa tissues 
reinforcing a role for YB-1 in PCa. 
Figure 1: YB-1 expression increases with increase 
in tumor grade and is negatively correlated with 
E-cadherin expression in human PCa tissues. 
Representative immunofluorescence images of human PCa 
tissues stained for YB-1 and E-cadherin. Human PCa tissue 
array containing a total of 42 cores; normal (n=8), low grade 
(n=7), high grade (n=21), and metastasis (n=6) was co-stained 
with anti pYB-1 (Green) and E-cadherin (Red) antibodies. 
Image acquisition settings were kept identical to ensure the 
comparability between individual groups. scale bar=50 µm 
(B) Box plot analysis of fluorescence intensity of images in A 
using the NIH image J software. p-values were calculated using 
GraphPad prism v5.0 as described. *p<0.05 and **p<0.01. 
Fluorescence intensities are represented as arbitrary units. DAPI 
was used as a nuclear staining control.
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Endogenous EMT induces YB1 expression
Aberrant overexpression of EGFR has been 
associated with both hormone-refractory and metastatic 
PCa and is accompanied with proliferation, survival, 
invasion and metastasis. EGF, the predominant ligand 
to EGFR/ErbB1 receptors has been shown to induce 
EMT in a variety of epithelial cancers including 
prostate [25-26]. A recent study has also shown peculiar 
YB-1 phosphorylation along with activation of YB-1 
interacting kinases including Akt, EGF and MEK in EGF 
treated PCa cell lines [27]. Taking these observations 
in consideration we sought to determine the expression 
and phosphorylation of YB-1 in an endogenous model of 
EMT using RWPE-1 cells. As anticipated we observed 
that exposure to EGF induced EMT like morphology in 
(Fig. 2A) that was associated with down regulation of 
E-cadherin and upregulation of vimentin as observed 
by immunofluorescence (Fig. 2B). Most importantly, in 
this model of EMT we observed YB-1 phosphorylation 
is significantly upregulated (Fig. 2C).These observations 
divulge a physiologically relevant role of YB-1 in 
endogenously induced EMT by EGF. 
YB-1 induces a mesenchymal phenotype in non-
tumorigenic prostate epithelial cells 
We first determined the expression of both pYB-1 
and YB-1 in non-tumorigenic and tumorigenic PCa cell 
lines. A higher level of YB-1 protein was observed in all 
tumorigenic PCa cells as compared to non-tumorigenic 
cells (Supplementary Fig. 2A). To elucidate whether 
YB-1 overexpression plays a role in the EMT in PCa we 
overexpressed YB-1 in non-tumorigenic RWPE-1 cells 
which mostly maintains an epithelial phenotype. Post 
transfected RWPE-1 cells showed approximately 4.3 fold 
increase in levels of YB-1 (Supplementary Fig. 2B), that 
was associated with morphological changes indicative 
of EMT (Fig. 3A). These cells grew as loose colonies 
of elongated cells compared to the cuboidal, compactly 
attached cells of control empty vector transfected cells. 
Similarly, we observed significant reduction in the 
transcript levels of epithelial markers viz. E-cadherin, 
desmoplakin, zona-occuldin-1 (ZO-1) and occludin 
along with induction in transcript levels of mesenchymal 
markers viz. N-cadherin, vimentin and fibronectin in the 
YB-1 overexpressed cells (Fig. 3B). Due to loss of cell 
viability (Supplementary Fig. 2C) and induction of EMT 
features it is difficult to sustain the growth of these cells in 
vitro. Addition of EGF (50 ng/ml) in YB-1 overexpressed 
cells significantly enhanced the viability and further 
sustained the EMT, suggesting the important role of 
extracellular growth/mitogenic signals in YB-1 mediated 
EMT (Fig. 3A). We observed significant reduction in 
epithelial markers and induction in the expression of 
mesenchymal markers that were further enhanced by 
EGF (Fig. 3C). We further confirmed the reduction in 
E-cadherin and induction in vimentin expression by 
immunofluroscence (Fig. 3D). We performed migration 
Figure 2: YB-1 Phosphorylation is increased in an endogenous EGF model of EMT. (A) Representative phase contrast 
images showing EGF induced mesenchymal like morphology in cells. RWPE-1 cells were cultured in complete KSFM medium for 24h. 
Cells were starved for 4h and then treated with or without EGF (50ng/ml) for 48h. (B) Representative immunofluroscent images showing 
low E-cadherin and increased vimentin expression in EGF treated cells. Scale bar=50 µm. (C) Western blot analysis showing that pYB-1 
Ser102 is induced in EGF treated cells. β-actin was used as a loading control.
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Figure 3: YB-1 induces EMT in non-tumorigenic prostate epithelial cells. (A) Representative images showing the effect of 
forced expression of YB-1 on mesenchymal like changes in RWPE-1 cells. RWPE-1 cells were transfected with empty vector or YB-1 
expression constructs, cultured in dishes and treated with EGF (50ng/ml). Scale bar = 50 µm. (B) Histogram showing the effect of YB-1 
induced changes in transcript levels of various EMT related markers in RWPE-1 cells. Expression of various epithelial and mesenchymal 
markers was analyzed by qRT-PCR. Each transcript level from empty vector cells was set as 1; *p<0.05 (C) Representative blots showing 
expression of various epithelial and mesenchymal markers analyzed by western blotting in YB-1 transfected cells treated with or without 
EGF (50ng/ml) for 24hr. (D) Representative images showing immunofluroscence staining for E-cadherin (epithelial) and vimentin 
(mesenchymal) in vector or YB-1 transfected cells in presence or absence of EGF (50ng/ml) for 24hr.Scale bar = 50 µm (E) Representative 
images showing that YB-1 enhances the migration of RWPE-1 cells. Vector- or YB-1-expressing cells were plated on top of a transwell 
chamber in media without EGF for 2 days. Images show cell migration in a wound closure assay. (F & G) Histograms showing migration 
and invasion (mean ± SD) of cells with YB-1 overexpression without EGF. Mean cell numbers/field ± SD of experiments performed in 
triplicate is shown. **p<0.01.
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and invasion assays in the same gain-of-function model 
and found significant enhancement in migration and 
invasion of YB-1 overexpressed cells when compared 
with control (Fig. 3E, F & G). These results confirm YB-1 
capability to induce EMT like changes and enhancement 
in cell migration and invasion rates in non-tumorigenic 
prostate cells which was further sustained by EGF, clearly 
suggesting the role of YB-1 in PCa disease progression 
and metastasis.
Identification of Fisetin, a small molecule inhibitor 
of YB-1 phosphorylation
Current literature for YB-1 clearly suggests its 
pivotal role in cancer initiation, progression and drug 
resistance; however little attention has been paid to it 
as a direct therapeutic target. Akt, an established kinase 
is an important regulatory kinase for YB-1 activation 
through phosphorylation at Ser102. Additionally, mTOR 
upstream to Akt is also known to regulate YB-1 at 
translational level. We have shown that fisetin, a plant 
derived small molecule as a potent inhibitor of PI3K/
Akt/mTOR pathway in different cancers including 
prostate. Based on the Akt/mTOR driven regulation 
of YB-1 we hypothesized that fisetin will inhibit Akt 
mediated YB-1 Ser102 phosphorylation. In order to 
assess this we initially performed molecular docking 
on the CSD of YB-1, known to be the most important 
domain for YB-1 Ser102 phosphorylation. Fisetin docked 
within the CSD on residues from β1 and β4 strands of 
YB-1 protein. Top-ranked energy scoring poses of fisetin 
share similar orientation patterns and binding modes 
as well as overlapping features on their hypothetical 
disposition within the binding site (Fig. 4A). Calculated 
free binding energy (ΔGb) for these conformations ranged 
from -11.9845 to -9.6273 kcal/mol, thus indicating 
good ligand-protein affinities. In particular, best energy 
docking conformation of fisetin showed consistent 
binding modes and tight affinity within the amino acid 
pocket that includes the following residues: Val63, Lys64, 
Trp65, Phe66, Ile91, Gly104, Asp105, Gly106, Glu107 
(Fig. 4B). The most favorable conformation places the 
catecholic moiety in close proximity to the Glu107 and 
the Glys104 and106, involving H-bond interactions with 
these residues, whereas an arene-arene stacking between 
the phenyl backbone of the chromen-4-one ring system 
and the Phe66 was observed (Fig. 4C). The other amino 
acid residues located near the binding site establish van 
der Waals and hydrophobic interactions with fisetin. 
Interestingly, the residue Trp65, considered to be very 
important for the activity of YB-1, is also contained in the 
Figure 4: Fisetin binds to the CSD of YB-1 protein. (A) In silico docking of fisetin within the putative binding site on CSD of 
YB-1. Top-ranked docking poses and representative view of the CSD domain. The protein is represented by cartoon, the binding site as 
molecular surfaces, and top-ranked energy poses as colored sticks. (B) Hypothetical disposition of the best energy fisetin docking pose 
within the CSD binding pocket of YB-1 protein. (C) Interaction of fisetin onto the CSD of YB-1 protein binding site. Amino acid residues 
(circles) are shown as follows: a) hydrophobic residues (green interior), b) polar residues (light purple), c) basic residues (blue ring), and 
d) acidic residues (red ring). Differences in solvent accessible surface area for fisetin ligand and for protein residues are plotted as a blue 
smud and a violet halo, respectively. The border of the binding pocket is marked by a dashed grey line. Dashed arrows denote H-bonds 
bonding (blue for H-bonds to the residue backbone, and green for H-bonds formed with the residue side chain), whereas the arrowheads 
indicate their direction (i.e., the donor is at the base of the arrow, and the acceptor is at the head). Green bis-arene rings within a dashed line 
denote possible arene-arene stacking. (D) Akt binds YB-1 in-vitro. LNCaP and PC3 cells were serum starved for 8h and treated with either 
EGF (50 ng/ml; lane 3 & 4) or EGF (50ng/ml) with fisetin (60 µM; lane 5&6) for 120 min then proteins from the cytoplasmic fraction were 
immunoprecipitated with the p-Aktser473 antibody. Lane 1 and 2 shows IgG control for both LNCaP and PC3 cells respectively.
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Figure 5: Fisetin inhibits EGF induced YB-1 phosphorylation and MTA-1 expression. (A) Representative immunofluorescent 
images of LNCaP cells treated with EGF and fisetin and stained for pYB-1 Ser102. Cells were serum starved for 24h and then treated with 
either EGF (50 ng/ml) alone or EGF (50 ng/ml) + fisetin (60 µM) for 120 min and processed for Immunofluroscent staining of pYB-1 Ser102. 
(B) Histograms represent relative YB-1 and MTA-1 mRNA expression (mean±s.d). LNCaP cells were treated as above and YB-1 and MTA-
1 gene expression measured at 24 & 48h by qPCR. *p<0.05.  (C) Immunoblot images of LNCaP cells treated as above and MTA-1 protein 
expression was measured at 24 & 48h by western blotting. (D) Representative immunofluorescent images of LNCaP cells serum starved 
for 24h and then treated with either with EGF (50ng/ml) alone or EGF (50 ng/ml) + fisetin (60 µM) for 48 h and stained for E-cadherin and 
vimentin. Scale bar in A and D=50 µm. (E) Histogram represents relative mRNA expression of EMT genes by qPCR. LNCaP cells treated 
as stated in D and further qRT-PCR analysis was done to quantify various EMT genes. *p<0.05, **p<0.01. 
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predicted binding pocket.
To estimate more reliable conditions of enzyme-
ligand complex in time-dependent manner, further 
explorative MD simulations were performed. The 
analyses revealed a consistent shifting of the flexible 
loop constituted by the sequence from Tyr99 to Val109. 
In particular, in the course of the experiment, the Ser102 
establishes molecular interactions with Glu107, also 
involving other residues such as Gly104 (Supplementary 
Fig. 3C), Tyr99 and Arg101 (Supplementary Fig. 3D 
& F). On the other hand, although several dynamic 
conformational changes of the protein were found, fisetin 
engaged in significant H-bond interaction with one 
catecholic hydroxyl and the Glu107, as well as Gly104 and 
Tyr99 (Supplementary Fig. 3C & F) during the simulation. 
Fisetin always docked within the predicted site thus 
promoting a stable ternary ligand-Glu107-Ser102 complex. 
In this scenario, we hypothesized that fisetin could be 
involved in stabilizing the Ser102-Glu107 interaction, 
thus affecting the function of Ser102. Interference with 
phosphorylation of YB-1 can indirectly affect the binding 
to DNA, thus preventing the function of transcription 
factor at a later stage. In order to confirm the modelling 
data we performed Plasmon Surface Resonance (PSR) 
and found that fisetin binds to YB-1 with an affinity of 
approximately 35 µM, with both slow association and 
dissociation (data not shown). 
We next performed immunoprecipitation 
experiments to see the effect of fisetin on YB-1/Akt 
interaction and observed significant loss in the interaction 
that confirmed our molecular docking experiments (Fig. 
4D). The above finding provided evidence that fisetin 
binds within the CSD region that might interfere with its 
binding with activating kinases and we confirmed this 
view by showing low interaction between Akt and YB-1. 
Fisetin inhibits EGF induced YB-1 
phosphorylation and EMT in PCa cells
Based on our data that pYB-1/YB-1 ratio is 
increased in the tumorigenic PCa cell lines, we next 
suppressed YB-1 expression by siRNA mediated gene 
silencing. As expected we observed significant reversal in 
cellular morphology towards an epithelial phenotype, and 
decrease in migration in the two PCa cell lines DU145 
and C4-2 (Supplementary Fig. 4A & B). We next tested 
the efficacy of fisetin on decreasing the phosphorylation 
of YB-1 expression in presence of EGF in another PCa 
cell line LNCaP. As shown in Fig. 5A fisetin (60µM; 24h) 
treatment significantly reduced the EGF induced YB-1 
phosphorylation. We also tested the effect of fisetin on 
YB-1 transcript levels and observed significant reduction 
at 48 h. Down regulation of MTA-1, a downstream target 
of YB-1 [28-30] further confirmed the effect of fisetin on 
YB-1. (Fig. 5B & C). 
Figure 6: Fisetin treatment inhibits YB-1 phosphorylation and EMT in vivo. (A) Representative immunofluorescent confocal 
images showing the expression of p-YB-1 Ser102 in tumor tissues from control and fisetin treated mice. Athymic nude mice were implanted 
with tumorigenic NB26 cells as described in the materials and methods section. Tumor tissues were harvested and processed for pYB-1 
staining. (B) Representative immunofluorescent confocal images showing the expression of E-cadherin and vimentin. As described above 
tissues from the same cohort were stained for both E-cadherin and Vimentin. Images were captured by a Nikon Confocal microscope using 
the same settings as described in materials and methods. Scale bar=50 µm. DAPI was used as a nuclear staining control.
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Next, we tested fisetin to inhibit the EMT in an EGF 
induced model of LNCaP cells. Cells treated with EGF 
exhibited decrease in epithelial makers E-cadherin and 
occuludin and increase in mesenchymal markers vimentin 
and snail. However, fisetin treatment resulted in significant 
recovery in the mRNA levels of epithelial marker 
E-cadherin but not occuludin. Similarly, fisetin treatment 
also down regulated the mRNA levels of vimentin and 
slug (Fig. 5D). In order to confirm the fisetin mediated 
inhibition of EMT at protein levels, we performed 
immunofluroscence staining of E-cadherin and vimentin in 
control, EGF, and EGF plus fisetin treated cells. As show 
in Fig. 5E control LNCaP cells showed strong E-cadherin 
expression and very low vimentin expression. However, 
EGF treatment decreased E-cadherin and enhanced 
vimentin fluorescence in LNCaP cells. Post EGF, 
treatment with fisetin (60µM; 24h) significantly recovered 
E-cadherin and suppressed the EGF induced vimentin 
expression. These results confirmed the potential of fisetin 
to inhibit the growth factor induced YB-1 phosphorylation 
and EMT in PCa cells.
Fisetin treatment inhibits EMT in vivo 
The in-vitro results prompted us to look forward for 
the similar effects in an in vivo scenario. We used nude 
mice implanted with the advanced PCa cell line NB26, 
known to be highly tumorigenic. Following the initial 
tumor growth the mice were given fisetin (1 mg/kg/per 
mice) for 28 days i.p. Post 28 days of fisetin treatment the 
mice were euthanized and tumors were harvested. Fisetin 
treatment significantly reduced both the tumor size and 
weight in the xenograft mice (data not shown), which 
corroborated well with our earlier findings showing fisetin 
as potent inhibitor of PCa progression (Khan et al.). We 
then performed immunofluroscence staining to assess the 
effect of fisetin on YB-1 phosphorylation and EMT related 
markers in the xenograft samples. We observed significant 
induction in the YB-1 phosphorylation in the non-treated 
tumor samples (Fig. 6A). Detailed analysis showed that 
pYB-1 Ser102 was localized in both cytoplasmic and 
nuclear compartments confirming earlier reports. We also 
observed loss of the epithelial marker E-cadherin and 
induction of mesenchymal markers vimentin and slug 
(Fig. 6B & C). Additionally, we also found significant 
induction of an important transcription factor slug known 
to be a target for YB-1 (Fig. 6D). These results confirmed 
that YB-1 phosphorylation is increased in PCa and also 
had a negative correlation with E-cadherin loss clearly 
corroborating the human PCa tissue immunofluorescence 
data. Next we stained the fisetin treated tumor samples for 
pYB-1 and observed significant decrease in the expression 
of pYB-1 both in cytoplasmic and nuclear compartments, 
clearly suggesting YB-1 as a target for fisetin (Fig. 6A). 
Further, we also checked the expression of EMT markers 
in these samples. As expected we observed significant 
induction in E–cadherin expression with concomitant 
reduction in vimentin (Fig. 6B & C). E cadherin is also 
known to be expressed in other cellular compartments 
and negatively influences processes like EMT and 
tumorigenesis. Fisetin induces E–cadherin expression not 
Figure 7: Fisetin inhibits TGF-β induced EMT in PCa cells. (A) Histograms represent relative mRNA expression (mean±s.d) 
of EMT related genes. LNCaP cells were treated with 0.5 ng/mL of TGF-β for the indicated durations and qRT-PCR was conducted using 
the specific primer pairs and probes for EMT related genes. Each transcript level from nonrelated cells was set as 1. *p<0.05, **p<0.01 
(compared with control). (B) Immunoblot images showing expression of EMT related proteins. LNCaP cells were treated as described in 
above for 24 h in the presence of fisetin (60 µM) and whole-cell extracts were made and analyzed by Western blot analysis with specified 
antibodies. β-actin was used as the loading control.
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only in the membranal but also in other compartments, 
suggesting strong effect of fisetin on E-cadherin re-
expression (Fig. 6B). These data clearly suggest that fisetin 
significantly reduces YB-1 phosphorylation and EMT. 
Fisetin inhibits TGF-beta induced YB1 expression 
and EMT in PCa cells 
TGF-β induced EMT is a well known model to 
identify novel compounds/small molecules as inhibitors. 
To strengthen our data that fisetin is a potent EMT 
inhibitor we tested its efficay in the TGF-β induced EMT 
model. As presented in Fig. 7A TGF-β exposure for 1h 
did not induce any significant effect on both epithelial 
and mesenchymal mRNA transcript levels in PCa cell line 
(22Rv1); however, 24h treatment of TGF-β significantly 
reduced the mRNA transcripts of epithelial markers 
i.e. E-cadherin and occuludin, and also subsequently 
increased the mRNA transcripts of mesenchymal markers 
i.e. vimentin and snail. Similar results were observed at 
protein levels. Fisetin treatment significantly reversed the 
effect of TGF-β, as Fig. 7B clearly shows concomitant 
upregulation of E-cadherin and down regulation of 
mesenchymal markers, vimentin and snail. No change 
in occludin expression was observed at protein levels by 
fisetin, suggesting additional mechanisms. These results 
confirmed that fisetin inhibits EMT process in a relevant 
model.
DISCUSSION
The major findings of this study are: (i) Forced 
overexpression of YB-1 in presence of EGF induces 
persistent EMT in non-tumorigenic prostate cells, (ii) 
YB-1 phosphorylation is strongly induced by EGF in 
prostate cells, (iii) YB-1 expression is inversely correlated 
with E-cadherin in human PCa samples, (iv) fisetin 
interacts within the CSD domain of YB-1 resulting in 
reduction in YB-1 phosphorylation at ser102 by reducing 
its interaction with activating Akt kinase and (v) fisetin 
inhibits EMT in both xenograft and in well-established 
in vitro TGF-β model suggesting its potential as an EMT 
inhibitor in PCa. 
YB-1 overexpression in non-tumorigenic prostate 
cells (RWPE-1) induced EMT like features; however 
these cells tend to lose the phenotype and also showed 
significant growth retardation. We believe there could be 
two possible explanations for this. It may be possible that 
these cells were not supported by extracellular growth 
signaling/factors like EGF, IGF, bFGF etc. known to 
phosphorylate YB-1, which seems to be important for its 
oncogenic function and EMT inducing properties. This 
notion is well supported by previous studies that showed 
that in the absence of activated PI3K-Akt, YB-1 functions 
as a tumor suppressor mainly by inhibiting the cap-
dependent translation [31]. Also, under similar conditions 
YB-1 showed growth suppressive properties [32]. 
Therefore, it can be speculated that YB-1 overexpression 
alone is not enough to induce a mesenchymal phenotype 
in non-tumorigenic epithelial cells. From our observations 
it seems that YB-1 mediated EMT program is a two tier 
mechanism, where YB-1 phosphorylation is enhanced 
by EGF and YB-1 further enhances the transcription and 
translation of vimentin and snail to confer mesenchymal 
like changes in the cells. However, it remains unclear 
whether the reduction of E-cadherin as observed in our 
results is a direct effect of YB-1 on its transcription and/
or translation. It is possible that upregulation of snail, a 
potent and established negative regulator of E-cadherin by 
YB-1 might be responsible for this, an argument that needs 
further validation [7, 33-36]. The increased migration rate 
of YB-1 overexpressed cells is in agreement with other 
previous studies [26], however one striking observation 
found in our study was that overexpressed cells showed 
significantly enhanced migration rate even in the absence 
of EGF, suggesting that YB-1 controls this property of 
cells without getting phosphorylated by upstream kinases. 
The enhanced migratory rate could also be supported by 
matrix degrading metalloproteases’s (MMP) known to be 
directly upregulated by YB-1 known to be involved in 
cellular migration [37-39]. 
EGF-induced EMT like morphology has been 
demonstrated as a crucial mechanism for the acquisition 
of invasiveness. EGF activates distinct signaling 
pathways, including ERK1/2, Akt, and Wnt to suppress 
the expression of epithelial proteins like E-cadherin and 
to increase the expression of mesenchymal proteins like 
vimentin. Recently EGF exposure to tumorigenic PCa 
cells was found to induce YB-1 phosphorylation in a dose 
and time dependent manner suggesting this signaling is a 
major effector of YB-1 mediated oncogenic function. Also 
YB-1 is known to regulate the expression of EGFR. We 
similarly observed that EGF exposure to non-tumorigenic 
PCa cells significantly enhanced YB-1 phosphorylation 
suggesting that EGF might utilize YB-1 to promote 
EMT and metastasis. This observation seems to be quite 
significant as activation of EGF-EGFR pathway has been 
associated with aggressiveness in PCa patients. 
After ascertaining the involvement of YB-1 during 
PCa EMT, we next focused on the identification of a 
possible YB-1 inhibitor. We chose to test fisetin for a 
number of reasons: (a) fisetin is a dual inhibitor of both 
PI3K/Akt pathways [22], which is one of the major kinase 
for YB-1 phosphorylation, (b) fisetin inhibits mTOR 
pathway [23-24], which is now shown to be important for 
YB-1 mRNA translation [40] and based on our previous 
observations fisetin inhibits the growth of PCa. As 
observed in molecular docking experiments fisetin directly 
interacted within the CSD of YB-1 protein, important for 
binding of kinases and to phosphorylate and activate YB-
1. Fisetin not only binds within the CSD of YB-1 but 
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also alters its topology. These results suggest that fisetin 
inhibits Akt mediated YB-1 phosphorylation mainly by 
interfering with its binding to the CSD. Elevated Akt 
activity in the cell did not affect expression levels of YB-
1, its subcellular localization, or general RNA-binding 
ability. Instead, phosphorylated YB-1 was less capable of 
cross-linking to the mRNA cap structure and of inhibiting 
cap-dependent translation of a reporter mRNA. These 
data suggest that YB-1 phosphorylation by Akt weakens 
its cap-binding capability; thereby facilitating translational 
activation of silenced mRNA species which mainly 
includes EMT related mRNA. Similar observations were 
made by [41] Law et al. 2010, using a small cell permeable 
peptide that binds within the flexible region and interferes 
with the 90 kDa ribosomal S6 kinase (RSK) binding with 
YB-1. We believe fisetin has several advantages over other 
strategies to inhibit YB-1. Fisetin not only decreases YB-1 
phosphorylation but also affects the labile pool of both 
cytosolic and nuclear YB-1. It also acts on the upstream 
kinases PI3K/Akt/mTOR to regulate the transcriptional 
and translational of YB-1. Finally, fisetin is a naturally 
occurring plant based flavonoid with no documented 
toxicity in vivo and is readily available. 
Based on these results we next tested fisetin to 
inhibit EMT in a widely accepted model of EMT induced 
by EGF and TGF-β. In PCa cells EGF induced the 
disruption of epithelial cell plasticity, upregulated snail, 
enhanced motility and invasion mainly through Akt-
dependent mechanisms, eventually promoting EMT and 
invasiveness [38].Fisetin reduces EGF induced YB-1 
phosphorylation and reverses EMT, suggesting fisetin’s 
EMT inhibiting potential. We also found that fisetin 
significantly reverses the TGF-β induced EMT in PCa 
cells. Whether TGF-β induces YB-1 phosphorylation and 
is important for EMT induction in PCa cells remains to be 
elucidated. It seems plausible that fisetin inhibits mTOR 
that is known to be upregulated by TGF-β and plays an 
indispensable role in TGF-β mediated EMT [42-43]. 
In summary, we provide evidence that YB-1 is 
upregulated in human PCa, has an inverse relationship 
with epithelial marker E-cadherin and its forced expression 
in non-tumorigenic PCa cells induces EMT and enhances 
cellular migration. We also provide evidence that a small 
molecule fisetin physically interacts with YB-1 and 
inhibits its activity and subsequently inhibits EMT both 
in vitro and in vivo.
METHODS
Cell culture 
The following human non-tumorigenic and 
tumorigenic cell lines were obtained from ATCC 
(Manassas, VA): RWPE-1, LNCaP, DU145, 22Rν1, 
PC-3, NB26 cells. Cell lines were characterized and 
authenticated by ATCC using a comprehensive database 
of short tandem repeat DNA profiles and maintained as per 
the recommendations of ATCC.
Plasmids
Full-length pcDNA-HATagYB-1, pcDNA (empty 
vector), FLAG-YB-1 and FLAG-empty vectors were 
obtained from Prof. Peter Mertens (Aachen, Germany) and 
Prof. Sandra E. Dunn (Vancouver, Canada). 
Cell transfections
For plasmid transfections, 1x106 cells (RWPE-1) 
were transfected with either 1 μg of pcDNA (empty vector) 
or pcDNA-HATagYB-1 vectors using Nucleofactor 
technology, Lonza (Anaheim, CA). After 6 hours medium 
was changed, cells were scraped 48hours for qPCR 
analysis and 72 hours for immunoblot analysis. 
siRNA 
ON-TARGETplus SMARTpool siRNA for YB-1 
and a nontargeting control siRNA were purchased from 
Dharmacon. Cells were incubated with siRNA (100 nM) 
and DharmaFECT reagent (#1) in antibiotic-free medium 
for 48 hours was used to transfect the cells. 
Real-time qPCR analysis for mRNA expression
Briefly, RNA was extracted from the non-
tumorigenic, tumorigenic and tumor tissue samples using 
Rneasy kit (Qiagen), and reverse transcribed with iScript 
Reverse transcription supermix kit (Biorad). cDNA (1-
100ng) was amplified in triplicate using gene specific 
primers (Table-1). Threshold cycle (CT) values obtained 
from the instrument’s software were used to calculate the 
fold change of the respective mRNAs. ΔCT was calculated 
by subtracting the CT value of the housekeeping gene from 
that of the mRNA of interest. ΔΔCT for each mRNA was 
then calculated by subtracting the CT value of the control 
from the experimental value. Fold change was calculated 
by the formula 2−ΔΔCT.
Cell viability assay
The effect of YB-1 overexpression (RWPE-1) and 
knockdown (DU145 and C4-2) on cell viability was 
determined by 3-[4,5-dimethylthiazol-2-yl]- 2,5-diphenyl 
tetrazolium bromide (MTT) assay. The absorbance was 
measured at 560 nm on a microplate reader (Bio-TEK 
Instruments).
Oncotarget2472www.impactjournals.com/oncotarget
Cell migration and invasion assays
Cell migration and invasion was performed by using 
the commercially available kits from Millipore (Billerica, 
MA) as per the manufacturer protocol. However, for non-
tumorigenic RWPE-1 cells KSFM complete medium with 
serum and for tumorigenic DU145 and C4-2 cells RPMI-
1640 supplemented with 10% FBS was added to the lower 
chambers. Experiments were conducted in triplicate for 
each cell line.
Immunofluorescence analysis 
4-8 μm thick sections were obtained from frozen 
blocks of tumor xenograft tissues, and mounted on 
superfrost plus slides. Slides were stored at −80°C until 
needed. Prior to staining procedure, slides were warmed 
at room temperature for 5 min and fixed in ice-cold 
acetone for 15 min at 4°C, followed by washing in PBS-
Tween 20 (x% PBST). LNCaP cells were  fixed with 2% 
paraformaldehyde and washed 3 times with ice cold PBS. 
Further both types of slides were then blocked with normal 
serum block (mention serum name and % of serum here. 
Ex. Normal goat serum etc) followed by incubation with 
different antibodies with appropriate dilutions as described 
in supplementary table 1. After rinsing in PBST, slides 
were incubated with fluorescent-conjugated secondary 
antibody at 1:500 dilution in blocking buffer. Slides 
were then rinsed in PBST, and sections were mounted 
with ProLong Gold Antifade reagent containing DAPI 
(Invitrogen) and left in dark overnight. Fluorescence 
imaging was performed using Nikon A1 confocal 
microscope ((Nikon Instruments Inc. New York, USA). 
Images were acquired with 20x objective at 1024 X 1024 
resolutions. Image analysis was accomplished using the 
Nikon Elements software. 
In silico molecular dynamics study
Ligand docking studies were performed using 
Molecular Operating Environment (MOE). Three-
dimensional structure of cold-shock domain (CSD) 
of Y-box binding protein-1 (YB-1) used for docking 
experiments was downloaded from the PDB Data Bank 
(http://www.rcsb.org/-PDB code:1h95). Before docking, 
the protein structure was properly protonated using the 
Protonate 3D option, and was geometrically optimized 
and minimized by employing AMBER99 force field with 
a generalized Born solvation model. The partial charges 
were automatically calculated. The structure of fisetin 
was built in MOE and minimized before the docking, 
using the MMFF94x force field, with the systematic 
algorithms until a RMSD gradient of 0.001 kcal mol-1 
Å-1 was reached. Rigid receptor-flexible ligand docking 
calculations were performed using the docking simulation 
feature MOE-dock by setting grid sizes that included the 
entire macromolecule. The triangle matcher was used 
as placement method to generate docking poses, and 
the London ΔGbinding scoring function that estimates 
the free energy of binding (kcal/mol) was used to rank 
hit candidates, after a force field based refinement and 
rescoring. Only the best scored poses generated in 
the docking experiments were retained and examined 
with MOE. After docking, a molecular dynamics (MD) 
simulation to the best docking complex was performed 
using the MD option (MOE-dynamic) included in the 
MOE suite of programs. Before MD experiment, a 
minimization energy calculation of the ligand-protein 
complex was conducted by using the above-mentioned 
procedure, until RMSD gradient 0.1. The other parameters 
were adjusted to default values, and the Nosé-Poincaré-
Andersen thermostat algorithm in a canonical number of 
particles, volume, and temperature (NVT ensemble), was 
used for creating ensemble trajectory. The temperature 
was raised from 0 to 300 K, while the other parameters 
were kept as default. After system equilibration, 300 ps of 
MD were recorded and six snapshots were considered (50, 
100, 150, 200, 250, and 300 ps).
In vivo tumor xenograft model 
Athymic (nu/nu) male nude mice (Harlan, USA) 
were housed under pathogen-free conditions with a 12-h 
light/12-h dark schedule and fed with an autoclaved diet ad 
libitum. We chose AR-positive NB26 cells for determining 
the in vivo effects of fisetin based on the fact that these 
cells form rapid and reproducible tumors in nude mice and 
also secrete PSA in the bloodstream of the host. Sixteen 
animals were then randomly divided into two groups, with 
8 animals in group 1 and 8 animals in group 2. The first 
group of animals received i.p. injection of DMSO (30 μL) 
and served as control. The animals of groups 2 received 
i.p. injection of fisetin (1 mg/animal) in 30 μL of DMSO 
twice weekly. Tumor sizes were measured twice weekly as 
described previously23. All animals of group 1 and group 
2 were sacrificed when tumors reached a volume of 1,200 
mm3 in the control group. All procedures conducted were 
in accordance with the guidelines for the use and care of 
laboratory animals. 
Statistical analysis
Data were analyzed using GraphPad Prism (version 
5; GraphPad Software). Two-tailed, unpaired t test was 
used. Data points in graphs represent mean ± SD, and p 
values < 0.05 were considered significant.
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